409 related articles for article (PubMed ID: 19014205)
1. A cost-utility comparison of four first-line medications in painful diabetic neuropathy.
O'Connor AB; Noyes K; Holloway RG
Pharmacoeconomics; 2008; 26(12):1045-64. PubMed ID: 19014205
[TBL] [Abstract][Full Text] [Related]
2. Long-term cost-effectiveness of initiating treatment for painful diabetic neuropathy with pregabalin, duloxetine, gabapentin, or desipramine.
Bellows BK; Nelson RE; Oderda GM; LaFleur J
Pain; 2016 Jan; 157(1):203-213. PubMed ID: 26397932
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
O'Connor AB; Noyes K; Holloway RG
J Am Geriatr Soc; 2007 Aug; 55(8):1176-84. PubMed ID: 17661955
[TBL] [Abstract][Full Text] [Related]
4. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy.
Bellows BK; Dahal A; Jiao T; Biskupiak J
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):153-64. PubMed ID: 22509775
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.
Choy E; Richards S; Bowrin K; Watson P; Lloyd A; Sadosky A; Zlateva G
Curr Med Res Opin; 2010 Apr; 26(4):965-75. PubMed ID: 20178405
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Liedgens H; Hertel N; Gabriel A; Nuijten M; Dakin H; Mitchell S; Nautrup BP
Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
[TBL] [Abstract][Full Text] [Related]
8. Career lifetime advances and key developments: diabetes.
Baglioni P; Govindan J; Khan A
Clin Med (Lond); 2007 Jun; 7(3):303-4. PubMed ID: 17639617
[No Abstract] [Full Text] [Related]
9. Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico.
Carlos F; Ramírez-Gámez J; Dueñas H; Galindo-Suárez RM; Ramos E
J Med Econ; 2012; 15(2):233-44. PubMed ID: 22082033
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.
Tanenberg RJ; Irving GA; Risser RC; Ahl J; Robinson MJ; Skljarevski V; Malcolm SK
Mayo Clin Proc; 2011 Jul; 86(7):615-26. PubMed ID: 21719618
[TBL] [Abstract][Full Text] [Related]
11. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
Athanasakis K; Petrakis I; Karampli E; Vitsou E; Lyras L; Kyriopoulos J
BMC Neurol; 2013 Jun; 13():56. PubMed ID: 23731598
[TBL] [Abstract][Full Text] [Related]
12. Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine.
Johnston SS; Udall M; Cappelleri JC; Johnson BH; Shrady G; Chu BC; Silverman SL
Am J Health Syst Pharm; 2013 Dec; 70(24):2207-17. PubMed ID: 24296843
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico.
Arreola Ornelas H; Rosado Buzzo A; García L; Dorantes Aguilar J; Contreras Hernández I; Mould Quevedo JF
Reumatol Clin; 2012; 8(3):120-7. PubMed ID: 22386298
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine for the treatment of painful diabetic peripheral neuropathy in Venezuela: economic evaluation.
Carlos F; Espejel L; Novick D; López R; Flores D
Medwave; 2015 Sep; 15(8):e6265. PubMed ID: 26460688
[TBL] [Abstract][Full Text] [Related]
15. Clinical inquiry: what medications are best for diabetic neuropathic pain?
Page N; Deluca J; Crowell K
J Fam Pract; 2012 Nov; 61(11):691-3. PubMed ID: 23256101
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK.
Beard SM; McCrink L; Le TK; Garcia-Cebrian A; Monz B; Malik RA
Curr Med Res Opin; 2008 Feb; 24(2):385-99. PubMed ID: 18157921
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of pharmacoeconomic studies for pregabalin.
Parker L; Huelin R; Khankhel Z; Wasiak R; Mould J
Pain Pract; 2015 Jan; 15(1):82-94. PubMed ID: 24815038
[TBL] [Abstract][Full Text] [Related]
18. Pregabalin and duloxetine for the treatment of neuropathic pain disorders.
Terneus W
J Pain Palliat Care Pharmacother; 2007; 21(1):79-84. PubMed ID: 17430838
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis.
Rudroju N; Bansal D; Talakokkula ST; Gudala K; Hota D; Bhansali A; Ghai B
Pain Physician; 2013; 16(6):E705-14. PubMed ID: 24284851
[TBL] [Abstract][Full Text] [Related]
20. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.
Burke JP; Sanchez RJ; Joshi AV; Cappelleri JC; Kulakodlu M; Halpern R
Pain Pract; 2012 Mar; 12(3):209-18. PubMed ID: 21676163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]